Development of a claims-based flare algorithm for systemic lupus erythematosus

References

• D'Cruz DP. Systemic lupus erythematosus. BMJ. 2006;332(7546):890–894.
   PubMed Web of Science ®Google Scholar
• Maidhof W, Hilas O. Lupus: an overview of the disease and management options. P T. 2012;37(4):240–249.
   PubMedGoogle Scholar
• Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(2):144–150.
   PubMed Web of Science ®Google Scholar
• Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.
   PubMed Web of Science ®Google Scholar
• Polachek A, Gladman DD, Su J, et al. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res. 2017;69(7):997–1003.
   PubMed Web of Science ®Google Scholar
• Nikpour M, Urowitz MB, Ibanez D, et al. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1152–1158.
   PubMed Web of Science ®Google Scholar
• Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology. 2017;56(suppl_1):i46–i54.
   PubMed Web of Science ®Google Scholar
• Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991;34(8):937–944.
   PubMed Web of Science ®Google Scholar
• Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology. 2012;51(3):491–498.
   PubMed Web of Science ®Google Scholar
• Petri M, Purvey S, Fang H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012;64(12):4021–4028.
   PubMed Web of Science ®Google Scholar
• Kan HJ, Song X, Johnson BH, et al. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Biomed Res Int. 2013;2013:808391.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Wilson K, Ogelsby A, et al. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med. 2013;55(11):1262–1270.
   PubMed Web of Science ®Google Scholar
• Golder V, Kandane-Rathnayake R, Hoi AY-B, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19(1):62.
   PubMed Web of Science ®Google Scholar
• Fangtham M, Petri M. 2013 Update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013;15(9):360.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Salmon JW, Kong SX, et al. Administrative databases and outcomes assessment: an overview of issues and potential utility. J Manag Care Spec Pharm. 1999;5(3):215–222.
   Google Scholar
• Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885.
   PubMed Web of Science ®Google Scholar
• Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867–868.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Framework for FDA’s real world evidence program [updated 2018 Dec; cited 2021 Jan 15]. Available from: https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RealWorldEvidence/UCM627769.pdf
   Google Scholar
• Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health. 1992;82(2):243–248.
   PubMed Web of Science ®Google Scholar
• Speyer CB, Li D, Guan H, et al. Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. Rheumatol Int. 2020;40(2):257–261.
   PubMed Web of Science ®Google Scholar
• Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ. 2013;16(5):667–677.
   PubMedGoogle Scholar
• Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20(5):453–462.
   PubMed Web of Science ®Google Scholar
• Garris C, Shah M, Farrelly E. The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims. Cost Eff Resour Alloc. 2015;13:9.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550–2558.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902–906.
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB, Ibanez D, et al. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67–70.
   PubMed Web of Science ®Google Scholar
• Ward MM. Development and testing of a systemic lupus-specific risk adjustment index for in-hospital mortality. J Rheumatol. 2000;27(6):1408–1413.
   PubMed Web of Science ®Google Scholar
• Deyo R, Cherkin D, Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Brier GW. Verification of forecasts expressed in terms of probability. Monthly Weather Rev. 1950;78(1):1–3.
   Google Scholar
• Murimi-Worstell IB, Lin DH, Kan H, et al. Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States. J Rheumatol. 2021;48(3):385–393.
   PubMed Web of Science ®Google Scholar
• Bell CF, Priest J, Stott-Miller M, et al. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA. Lupus Sci Med. 2020;7(1):e000357.
   PubMed Web of Science ®Google Scholar
• Thanou A, Chakravarty E, James JA, et al. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology. 2014;53(12):2175–2181.
   PubMed Web of Science ®Google Scholar